HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $6 price target.
August 07, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Elevation Oncology and maintained a $6 price target.
The reiteration of a Buy rating and the maintenance of a $6 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100